Apellis Pharmaceuticals Inc. (APLS) stock soared 5.07% in Tuesday's intraday trading session, outperforming the broader market.
The rally in APLS shares came after JP Morgan maintained its "Overweight" rating on the biopharmaceutical company. Analysts at the investment bank reiterated their positive stance on Apellis, likely boosting investor confidence in the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.